| Identification | More | [Name]
Pravastatin sodium | [CAS]
81131-70-6 | [Synonyms]
3BETA-HYDROXYCOMPACTIN, NA
(BETA R,DELTA R,1S,2S,6S,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-BETA,DELTA,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-1-NAPHTHALENEHEPTANOIC ACID MONOSODIUM SALT
(BETAR, DELTAR,1S,2S,6S,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-BETA, DELTA,6-TRIHYDROXY-2-METHYL-8[(2S)-2-METHYL-1-OXOBUTOXYL]-1-NAPHTHALENEHEPTANOIC ACID SODIUM
(BETA-R,DELTA-R,1S,2S,6S,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-BETA,DELTA,6-TRIHYDROXY-2-METHYL-8[(2S)-2-METHYL-1-OXOBUTOXYL]-1-NAPHTHALENEHEPTANOIC ACID NA
ELISOR
EPTASTATIN SODIUM
KOPOSTAT
MEVALOTIN
PRAVACHOL
PRAVASELECT
PRAVASTATIN SODIUM
PRAVASTATIN SODIUM SALT
1-naphthaleneheptanoicacid,1,2,6,7,8,8a-hexahydro-2-methyl-8-(2-methyl-1-oxob
2-alpha,6-alpha,8-beta(r*),8a-alpha))-*
cs-514
epastatinsodium
lipostat
sq31000
utoxy)-beta,delta,6-trihydroxy-,monosodiumsalt,(1s-(1-alpha(beta-s*,delta-s
Pravastatin Sodium (US Pat 1981) | [EINECS(EC#)]
1806241-263-5 | [Molecular Formula]
C23H36NaO7 | [MDL Number]
MFCD00887601 | [Molecular Weight]
447.52 | [MOL File]
81131-70-6.mol |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Powder | [Melting point ]
171.2-173 °C
| [storage temp. ]
2-8°C
| [solubility ]
H2O: 19 mg/mL
| [form ]
powder
| [color ]
white
| [biological source]
synthetic (organic) | [Water Solubility ]
water: 100mg/mL | [Usage]
A competitive inhibitor of HMG-CoA reductase. Bioactive metabolite of Mevastatin | [Merck ]
14,7714 | [BCS Class]
1 (CLogP), 3
(LogP) | [Stability:]
Hygroscopic | [InChIKey]
AOGODJAJIRDKOP-ZSXJCKEYNA-N | [SMILES]
[NaH].OC(=O)C[C@@H](C[C@@H](CC[C@@H]1[C@]2([H])C(=C[C@H](C[C@@H]2OC(=O)[C@H](CC)C)O)C=C[C@@H]1C)O)O |&1:5,7,10,11,15,17,21,28,r| | [CAS DataBase Reference]
81131-70-6(CAS DataBase Reference) |
| Questions And Answer | Back Directory | [Preparation]
1. Preparation of Pravastatin Sodium: A method for manufacturing pravastatin sodium that significantly reduces the amount of organic solvent used and efficiently obtains pravastatin sodium with a drastically reduced content of similar substances using a simple method. The method comprises the following steps: (a) preparing a mixture of crude pravastatin and/or its salt with ethyl acetate; (b) dissolving the mixture in a mixture of ethanol and water to prepare a solution; and (c) adjusting the pH of the solution to 9 or higher, and then precipitating pravastatin sodium in the presence of sodium ions.
2. Preparation of Pravastatin Sodium Tablets: Pravastatin sodium tablets are prepared using a direct powder compression method.
1) Formulation: 103.71g of pravastatin sodium raw material, a certain amount of MCC mannitol PVP K30, and 207.4g of magnesium oxide are added to a wet-mixing granulator and mixed evenly. Then, 50g of CMS-Na is added as a disintegrant and 20g of magnesium stearate is added as a lubricant. After mixing evenly, the mixture is directly compressed into tablets, each containing 10mg of pravastatin sodium.
2) Tableting: The intermediate is added to the hopper of the tableting machine. Tableting parameters: turntable speed 21.0r/min, current main compression pressure 0.12KN, current dispensing pressure 0.24KN, tablet thickness 1.7mm, filling depth 7.4mm, pre-compression thickness 3.5mm.
3) Coating: OY-C-7000A gastric-soluble film coating premix is dissolved in 80% ethanol to prepare a coating solution with a solid content of 8%. The solution is then coated in a coating pan, resulting in a 4% weight gain. Coating parameters: coating pan rotation speed 6.0 r/min, inlet air temperature 52℃, outlet air temperature 28℃, atomization pressure 0.2 MPa, coating solution flow rate 15 ml/min. |
| Safety Data | Back Directory | [Hazard Codes ]
F,C | [Risk Statements ]
R11:Highly Flammable.
R34:Causes burns. | [Safety Statements ]
S16:Keep away from sources of ignition-No smoking .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . | [RIDADR ]
3077 | [WGK Germany ]
2
| [RTECS ]
QJ7185000
| [HazardClass ]
9 | [PackingGroup ]
III | [HS Code ]
29329990 | [Storage Class]
11 - Combustible Solids |
| Hazard Information | Back Directory | [Chemical Properties]
White Crystalline Powder | [Originator]
Apo-Pravastatin ,Apotex Inc., Canada | [Uses]
A competitive inhibitor of HMG-CoA reductase. Bioactive metabolite of Mevastatin | [Uses]
An HMGCR inhibitor which blocks cholesterol synthesis | [Uses]
antihyperlipidemic, HMGCoA reductase inhibitor | [Uses]
Pravastatin sodium is the salt of pravastatin, a ring-opened member of the statin family. Pravastatin is produced biosynthetically from compactin (mevastatin) by a number of microorganisms, notably Absidia, Cunninghamella, Syncephalastrum, Nocardia or Streptomyces. Typically, statins like compactin, lovastatin and simvastatin possess a β-hydroxy lactone ring which is a pro-drug for the readily ring-opened dihydroxyacid generally regarded as the active HMG-CoAreductase inhibitor. Importantly, the free carboxylic acid enables pravastatin to be freely water soluble within biological pH ranges. | [Definition]
ChEBI: An organic sodium salt that is the sodium salt of pravastatin. A reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), it is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but
has the advantage of fewer side effects compared with lovastatin and simvastatin. | [Manufacturing Process]
Pravastatin was isolated as products of enzymatic hydroxylation by some kinds of microorganisms of [1S-[1-α(R*),7β,8β(2S*,4S*)8αβ]]-2methylbutanoic acid 1,2,3,7,8,8a-hexahydro-7-methyl-8-[2-(tetrahydro-4hydroxy-6-oxo-2))-pyran-2-yl)ethyl]-1-naphthalenic lactone (campactin) or their carboxylic acid or their salts (products of animal metabolism of microorganisms from the genera Nocardia, Streptomyces et cetera).
Pravastatin may be preparated by using the microorganisms of genera Nocardia (method 1) and Mortierella (method 2).
Method 1
Cultivation of Nocardia autotrophica subsp. amethystineCells of Nocardia autotrophica subsp. amethystina FERM P-6183 was inoculated from a slant culture by means of a platinum loop into each of twenty 500 ml Erlenmeyer flasks, each containing 100 ml of a culture medium having the following composition: glucose - 1.0%, peptone - 0.2%, meat extract - 0.1%, yeast extract - 0.1%, corn steep liquor 0.3%, tap water balance..
Shaking was then carried out at 26°C and 220 r.p.m. for 2 days, at which time sodium 2-methyl-8-(2-methyl-1-oxobutoxy)-β,δ-dihydroxy(1S-(1-α(βS*,δ-S*),2-α,6-α,8-β(R*),8a-α))-1-1,2,6,7,8,8ahexahydronaphthaleneheptanoate was added to a final concentration of 0.05% w/v. Incubation was continued at 26°C and 220 r.p.m. for a further 5 days.
Preparation of pravastatin
After completion of the cultivation, the reaction mixture was filtered and the pH of the filtrate was adjusted to a value of 3 by the addition of trifluoroacetic acid. The acidified filtrate was then extracted three times, each with 1 liter of ethyl acetate, to give extracts containing a mixture (6-α and 6-β) of (1S-(1α,β- S*,δ-S*),2-α,8-βR*),8a-α))-1-naphthaleneheptanoic acid 1,2,6,7,8,8ahexahydro-2-methyl-8-(2-methyl-1-oxobutoxy)-β,δ,6-trihydroxy.
This extract was then immediately transferred into a 5% w/v aqueous solution of sodium hydrogen carbonate, and the pH of the mixture was adjusted to a value of 7.0 by the addition of 2 N hydrochloric acid. The mixture was then adsorbed on a Diaion HP-20 column. The column was washed with water and then eluted with 50% v/v aqueous acetone to give a fraction containing (1S(1-α,β- S*,δ-S*),2-α,6-α,8-βR*),8a-α))-1-naphthaleneheptanoic acid 1,2,6,7,8,8a-hexahydro-2-methyl-8-(2-methyl-1-oxobutoxy)-β,δ,6-trihydroxy-, monosodium salt (pravastatin). This was freeze-dried, to give 200 mg of pravastatine.
Method 2
Cultivation of Mortierella maculata nov. spec. E-97 [NCAIM(P)F 001266]
A spore suspension was prepared with 5 ml of a 0.9% sodium chloride solution obtained from a 7-10 day old, malt extract-yeast extract agar slant culture of Mortierella maculata nov. spec. E-97 [NCAIM(P)F 001266] strain able to 6-β-hydroxylate compactin and the suspension was used to inoculate 100 ml inoculum medium PI (glucose-50 g, soybean meal-20 g, in 1000 ml tap water) sterilized in a 500 ml Erlenmeyer flask.
5 liters working volume a bioconversion culture medium is prepared (glucose20 g, glycerine-20 g, soybean meal-20 g, peptone-5 g, potassium dihydrogen phosphate-0.5 g, polypropylene glycol 2000-1 g, in 1000 ml tap water); the components of the culture medium are added corresponding to 5 liters. Then it was sterilized for 45 min at 121°C and seeded with 500 ml of the inoculum culture.
Before sterilization the pH of the medium was adjusted to 7.0 value.
The fermentation was carried out at 28°C, with a stirring rate of 400 rpm andwith an aeration rate from bottom direction 60 liters/hour for 4 days. At the 2nd day after the transfer the culture started to foam heavily, which can be decreased by the addition of further polypropylene glycol 2000. The pH reached 6.3-7.5 by the 4th day. The feeding of the sodium 2-methyl-8-(2methyl-1-oxobutoxy)-β,δ-dihydroxy(1S-(1-α(β- S*,δ-S*),2-α,6-α,8-β(R*),8aα))-1-1,2,6,7,8,8a-hexahydronaphthaleneheptanoate substrate is allowed to be started if the pH of the broth is above 6.3.
Preparation of pravastatinAt the 4th day of the fermentation 2.5 g compactin substrate is added in sterile filtered aqueous solution. Calculated for the volume of the broth 0.51.0% glucose was added into the culture depending on the pH in the form of 50% solution sterilized at 121°C for 25 min in parallel with the substrate feeding. After 24 hours the compactin substrate is consumed from the culture (is detected by HPLC) and was converted to pravastatin. By lyophilization of the aqueous residue 1.3 g pravastatin was obtained. The chromatographically pure product was crystallized from a mixture of ethanol and ethyl acetate. Melting point: 170-173°C (decomp.). | [Brand name]
Pravachol
(Bristol-Myers Squibb). | [Therapeutic Function]
Antihyperlipidemic | [General Description]
A water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that potently blocks in vivo cholesterol synthesis (Ki = ~1 nM). Offers cardioprotection. Also acts as an immunomodulator and an inhibitor of ras p21 isoprenylation. | [Biological Activity]
Water-soluble, competitive inhibitor of 3-hydroxy-3-methyl coenzyme A (HMG-CoA) reductase. Potently blocks cholesterol synthesis in vivo (K i ~ 1 nM) and displays cardioprotective properties. | [Biochem/physiol Actions]
Primary TargetAMG-CoA reductase | [Clinical Use]
HMG CoA reductase inhibitor:
Hypercholesterolaemia | [Drug interactions]
Potentially hazardous interactions with other drugs
Antibacterials: increased risk of myopathy with
daptomycin, fusidic acid (avoid) and telithromycin;
concentration increased by clarithromycin and
erythromycin.
Antivirals: increased risk of myopathy with
atazanavir and boceprevir; concentration possibly
increased by darunavir; concentration reduced by
efavirenz.
Ciclosporin: increased risk of myopathy.
Colchicine: possible increased risk of myopathy.
Lipid lowering agents: increased risk of myopathy
with fibrates, gemfibrozil (avoid) and nicotinic acid. | [Metabolism]
Pravastatin undergoes extensive hepatic metabolism to a
relatively inactive metabolite. About 70% of an oral dose
of pravastatin is excreted in the faeces, as unabsorbed
drug and via the bile. | [storage]
Desiccate at RT | [References]
[1] bolego c, poli a, cignarella a, catapano al, paoletti r. novel statins: pharmacological and clinical results. cardiovasc drugs ther. 2002 may;16(3):251-7.
[2] keidar s, aviram m, maor i, oiknine j, brook jg. pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. br j clin pharmacol. 1994 dec;38(6):513-9.
[3] menter dg, ramsauer vp, harirforoosh s, chakraborty k, yang p, hsi l, newman ra, krishnan k. differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. plos one. 2011;6(12):e28813. |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 18918157536; |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Adamas Reagent, Ltd.
|
| Telephone: |
4006009262 13023226327 |
| Website: |
http://www.tansoole.com |
| Company Name: |
China Langchem Inc.
|
| Telephone: |
0086-21-58956006 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList19141/0_EN.htm |
|